Nisa Investment Advisors
PRLD icon

Nisa Investment Advisors’s Prelude Therapeutics PRLD Stock Holding History

Nisa Investment Advisors’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.71K Hold
1,634
– – ﹤0.01% 2507
2026
Q1 		$5.59K Hold
1,634
– – ﹤0.01% 2430
2025
Q4 		$4.74K Hold
1,634
– – ﹤0.01% 2459
2025
Q3 		$2.35K Hold
1,634
– – ﹤0.01% 2587
2025
Q2 		$1.32K Buy
1,634
+1,234
+309% +$1.07K ﹤0.01% 2688
2025
Q1 		$307 Sell
400
-108
-21% -$101 ﹤0.01% 2868
2024
Q4 		$648 Buy
+508
New +$674 ﹤0.01% 2773
2024
Q3 		– Sell
-2,100
Closed -$8K – 3026
2024
Q2 		$8K Buy
+2,100
New +$8.55K ﹤0.01% 2203
2023
Q4 		– Sell
-37
Closed -$114 – 2725
2023
Q3 		$114 Sell
37
-3,963
-99% -$14.9K ﹤0.01% 2728
2023
Q2 		$18K Hold
4,000
– – ﹤0.01% 2134
2023
Q1 		$23K Hold
4,000
– – ﹤0.01% 1968
2022
Q4 		$24K Hold
4,000
– – ﹤0.01% 2014
2022
Q3 		$27K Hold
4,000
– – ﹤0.01% 1970
2022
Q2 		$21K Buy
+4,000
New +$20.4K ﹤0.01% 2041

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Nisa Investment Advisors's PRLD Position: Q2 2026 in Review

Nisa Investment Advisors held its Prelude Therapeutics (PRLD) position steady in Q2 2026 at 1,634 shares worth $8.71K. The position accounts for ﹤0.01% of the portfolio, ranked #2507.

Nisa Investment Advisors first reported a position in PRLD in Q2 2022 and has held it in 14 quarters since. The position peaked at $27K in Q3 2022. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Nisa Investment Advisors held 1,634 shares of Prelude Therapeutics worth $8.71K as of Q2 2026.
  • Nisa Investment Advisors left its Prelude Therapeutics share count unchanged in Q2 2026.
  • Prelude Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2507 holding.
  • Nisa Investment Advisors first reported a position in Prelude Therapeutics in Q2 2022 and has held it in 14 quarters since.
  • Nisa Investment Advisors's Prelude Therapeutics position peaked at $27K in Q3 2022.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.